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Antibiotics are the main, and often only, clinical intervention for prophylactic and active treatment of bacterial infections in
humans.Perhapsit isnot surprisingthat thesedrugsalso shiftthe compositionofcommensal bacteriainsideourbodies,especially
those within the gut microbial community (microbiota). How these dynamics ultimately aﬀect the function of the gut microbiota,
however, is not fully appreciated. Likewise, how antibiotic induced changes facilitate the outgrowth and pathogenicity of certain
bacterial strains remains largely enigmatic. Here, we discuss the merits of a microbial ecology approach toward understanding
a common side eﬀect of antibiotic use, antibiotic-associated diarrhea (AAD), and the opportunistic bacterial infections that
sometimes underlie it. As an example, we discuss how this approach is being used to address complex disease dynamics during
Clostridium diﬃcile infection.
Copyright © 2008 S. T. Walk and V. B. Young. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The human colon contains the most abundant and diverse
assemblage of bacteria in the body. Symbiotic interactions
with and within this complex community are now recog-
nized as important predictors of human health. Aberrant
community structures are associated with complex diseases
like obesity, irritable bowel syndrome, and immune dys-
function. Antibiotic administration can disrupt the colonic
ecosystem, which, in turn, leaves patients vulnerable to
gastrointestinaldisease.Diarrheaisacommonmanifestation
of antibiotic-mediated disturbance and can result from
alteredfunctionofthedisruptedmicrobiota,directeﬀectson
hosttissue,andcolonizationbyopportunisticorganismsthat
invade the altered microbial community. Here, we review the
relevant microbial ecology of antibiotic-associated diarrhea
with an emphasis on bacterial community dynamics during
C. diﬃcile infection.
2. COMMONALITIES AND ASSUMPTIONS FOR
GI TRACT MICROBIAL ECOLOGY
When initiating a discussion of the microbial ecology of
the gastrointestinal (GI) tract, it is important to review
some of the common areas and assumptions investigators
used when studying this ecosystem. First, the proportion
of uncultivable bacteria in the GI tract is high (∼60%–
80%). Initially, culture-based surveys of the gut microbial
successfully isolated and characterized large numbers of the
bacterial morphotypes (i.e., distinct cellular forms) present
in human feces [1, 2]. However, recent surveys based on
DNA sequencing have indicated that the vast majority
of genetically distinct organisms have not been isolated
by culture techniques [3]. These relatively new sequence-
basedapproachesincombinationwithrobustbioinformatics
provide the framework to explore a vast amount of genetic
diversity. It is now feasible to survey nearly all of the genetic
information in a given system, and this ability has ushered in2 Interdisciplinary Perspectives on Infectious Diseases
a new area of research, referred to as metagenomics [4]. The
ﬁeld is still in its infancy, and much of the data continue to
be open for interpretation. It is important to note that the
currency for GI tract microbial ecology in the metagenomic
era is the abundance and distribution of targeted DNA
sequences and not actual organisms or randomly sampled
genomes of organisms. The ampliﬁcation, cloning, and
sequencing of certain loci, such as the highly conserved 16S
rRNA locus, are the tools used to study the phylogenetic
signal contained in the metagenome, and this is diﬀerent
than classical metagenomics, where one seeks to analyze
the functional and sequence-based diversity contained in
all microbial genomes of communities [4, 5]. Lastly, we
draw attention to an early few studies that use culture-based
approaches, but will put these data into a metagenomic
context.
There are measurable, statistical, and real diﬀerences
(i.e., not all the detectable diﬀerences are biologically sig-
niﬁcant) between the bacterial communities throughout the
human body (skin, mouth, vagina, GI tract, etc.). Studies
have shown regional diﬀerences in microbial composition
throughout the mammalian GI tract in both the longitudinal
(i.e., stomach to small intestine to large intestine) and axial
(i.e., mucosal associated to mucus to lumen) directions [6–
8]. For further discussion on this topic, see the recent review
by Peterson et al. [7]. Currently, most studies circumvent
the practical and ethical problems associated with direct
intestinal sampling (e.g., via colonoscopy and biopsy) by
using feces as a proxy [9]. Many of the studies reviewed
here do the same and regard the bacterial community in
feces as representative of the gut microbiota as a whole, with
the caveat that existing spatial community diﬀerences may
result in a biased representation. For example, total anaerobe
countswerefoundtobe100timeslowerinthehumancecum
compared to feces [10].
Lastly, it is generally assumed that the abundance and
distribution of an organism (16S rRNA gene sequence)
and broader taxonomic groups of organisms (sequences
grouped based on percent similarity and called operational
taxonomic units or OTUs) are important. The abundance
and distribution of OTUs are often called community
structure. As we will discuss in detail below, there are
observable patterns in the gut microbiota under certain
conditions. Some taxonomic groups are very abundant,
while others are at such low abundance that they can only
be detected using highly sensitive and speciﬁc molecular
techniques. Most studies look for community structure and
try to assess the underlying mechanisms that caused it
(disease, diet, drug eﬀect, etc.). While this may at ﬁrst
seem logical and perhaps trivial, it is currently not well
understood what these patterns really mean. For example,
what OTUs should be used to assess structure? At the
phylum level, patterns may be clear, but at the species
level, where functional variation is driven by evolutionary
processes, the structure may not be statistically diﬀerent
from a random assemblage (due, in part, to the lack of
a universal bacterial species concept [11]). Currently, a
challenge for microbial ecologists is to understand dynam-
ics with respect to the functional attributes of bacterial
communities and not only through the lens of taxon-
omy.
3. NORMAL GUT MICROBIOTA
The human colon is typically associated with 1011 to 1012
bacterial cells per gram of contents, and new estimates using
genetic diversity suggest that the gut ecosystem holds 15000–
36000 diﬀerent species [9, 12, 13]. Colonization normally
begins at birth, and a variety of bacteria can be detected in
infant stools within the ﬁrst few days after vaginal delivery
[14]. Among the ﬁrst gut bacteria to colonize infants were
Escherichia coli and Staphylococcus aureus [15, 16]. These
studies used culture-based methods to show that abundance
was highest at about one week after birth and decreased 1–
3 orders of magnitude within the ﬁrst year, suggesting that
the abundance of early bacterial colonizers is subsequently
shifted by the growing biologic complexity of this system.
Recently, nonculture-based data supported these ﬁndings
and showed that multiple shifts occur among diﬀerent
taxonomic groups over the ﬁrst 200 days of life [17]. Also,
the gamma-Proteobacteria, to which E. coli belongs, appear
to be the dominant members in these infant’s GI tract. It
is interesting to note that E. coli was initially discovered
in 1884 and studied by the famous German pediatrician
TheodorEscherichbecauseofitspresencein“normal”infant
microbiota and because of its beneﬁcial eﬀects on digestion
[18].
Deﬁning normal gut microbiota is challenging because
of the compositional heterogeneity that exists between hosts
[19]. Most phylotypes (suspected species) are unique to
the individual being sampled [3]. At broader taxonomic
levels, a consistent community structure is often observed,
leading to the conclusion that the gut is dominated by
members of a few bacterial phyla (Firmicutes, Bacteroidetes,
Actinobacteria, and Proteobacteria). The human gut is
described as “exclusive” because there are more divisions
(phyla) of bacteria and archaea known to exist on earth than
whatistypicallysampledfromhumansubjects(currentlythe
Silva 16S rRNA database has 115 bacterial divisions of which
only 10 have been sampled from humans) [7].
The bacteria in our GI tract are important for certain
aspects of human health, and there are clear mutualisms
between human and bacterial cells [20]. Not surprisingly,
our immune system defends against negative symbiotic
interactions based on prior exposure and also on stimulating
mechanisms like breast feeding and vaccinations (prior
exposure tolivingcellsisnotalwaysnecessaryforaneﬀective
immune response). Some of the traits that make us human
also dictate the structure of the gut community, as the
microbiota of conspeciﬁc relatives (same species of humans,
primates, and nonprimates) was most similar to each other
in a recent study [21]. There are few data that describe
the community structure of the GI tract microbiota in
healthy individuals and this limits our ability to formulate
generalities on the normal state. However, if we are to
consider the healthy human gut as a theoretically-based
community, where a consistent structure is deﬁned and
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should converge upon a similar structure under similar
conditions [22]. In the absence of convergence, we are left
to the study of stochastic events and patterns that are best
explained by random walk models, where species traits
do not correlate with the abundances along environmental
gradients (for more on the theoretical issues concerning
community analysis, see Tilman [22]).
Because of the low degree of similarity between individ-
uals, changes in the gut microbiota are typically measured
by shifts in structure. For example, a cohort study of 1032
infants showed that breast-fed infants have a consistently
diﬀerent bacterial composition than bottle-fed infants [23].
Based on real-time PCR and OTU speciﬁc probes, formula-
fed infants (n = 232) were colonized by E. coli, C.
diﬃcile,B.fragilis,andlactobacillimoreoftenthanbreast-fed
infants (n = 700). Similar comparative studies have shown
associationsbetweenanalteredgutmicrobiotaandanumber
of human diseases, including obesity [24], Crohn’s disease
[25], irritable bowel syndrome [26], and allergies [27]. It is
clear that our understanding of the normal gut microbiota is
limitedandjustbeginning,butcomparativestudieslikethese
illustrateanovelabilitytodescribethemicrobialecologythat
underlies many complex diseases.
4. ANTIBIOTICS INCREASE HOST SUSCEPTIBILITY
TO PATHOGENS
One measure of ecosystem stability, in terms of maintaining
function [28], is the ability to resist invasion and subsequent
dominance by immigrating organisms. For the gut ecosys-
tem, antibiotic therapy represents a strong perturbation
that shifts the relative proportion of community members,
allowing opportunists to establish [29–32]. Antibiotic ther-
apies exclude members of the community by eradicating
them directly or indirectly by breaking necessary mutualistic
interactions [33]. During such events in murine models, the
community structure was disrupted and enteric pathogens
reached high numbers [34, 35]. Similar observations under-
lie the proposed colonization resistance or barrier function,
provided to the host by the gut microbiota [32, 36, 37],
preventing the ingress of pathogens into the gut ecosystem.
Many details about the colonization resistance function
of the microbiota have yet to be tested, but it is clear
that shifts in the gut microbial community structure are
permissive to the establishment of certain pathogens. For
example, Vibrio cholerae does not normally cause disease in
conventionalguineapigs,butitestablishedandcausedsevere
disease after disruption of the microbiota by pretreatment
with streptomycin [38]. Similarly, it has been shown that
mice with a conventional gut microbiota require a much
higher infective dose (109 colony forming units per mL,
CFU/mL) for colonization by a gram-negative bacterium
compared to antibiotic treated mice (102 CFU/mL) [39].
The mechanisms behind colonization resistance in humans
are topics of ongoing research, but the gut microbiota
in animal models has been shown to (i) utilize essential
nutrients before they are available to invading bacteria
(resource limitation), (ii) limit access to attachment sites
(space limitation), and (iii) produce inhibitory substances
[40].
Many factors, including drug dose, route of administra-
tion, absorption, and host inactivation, dictate the intensity
of antibiotic eﬀects on the gut microbiota (see review by
Sullivan et al. [32]f o rs p e c i ﬁ ce ﬀects of commonly used
drugs). A number of culture-based and nonculture-based
molecular techniques have been used to follow bacterial
community dynamics in humans upon exposure to antibi-
otics. Often, speciﬁc groups of OTUs are singled out with
speciﬁc probes. Temporal eﬀectsofantibiotic treatmentwere
recentlyshownamongmembersoftheBacteroidetesdivision
using culture techniques and genetic ﬁngerprinting (rep-
PCR) [30]. During a case-control study of subjects taking
capsules of 150mg clindamycin (orally), each individual was
sampled prior to antibiotic treatment and at set time points
throughout the following 2-year posttreatment. The overall
diversity of this division decreased upon antibiotic treatment
and remained reduced during the entire 2 years of the
study. The authors also show that the dominant community
members changed markedly in relative abundance during
the ﬁrst 3 weeks of the posttreatment, suggesting that these
eﬀects were not exclusive to the rest of the microbiota.
Wedrawattentiontothesedynamicsheretosimplypoint
out that the gut microbiota changes markedly during and
after normal therapeutic courses of antibiotics and that host
susceptibility to subsequent infection is increased as a result.
We now turn to speciﬁc clinical presentations that result
from antibiotic treatment of human patients and follow




Patients undergoing antibiotic treatment often develop
diarrhea (antibiotic-associated diarrhea or AAD) as a side
eﬀect of therapy. Approximately, 5%–25% of patients on
antibiotic therapy develop AAD, which can range from
a mild, self-limiting illness to a serious and progressive
pseudomembranous colitis [41, 42]. The risk of developing
disease is highly variable and depends on host factors (age,
diet, immune system function, etc.), the type and dose of
antibiotic, and the duration of treatment. In a cohort study,
Beaugerie et al. found that 17.6% (46 out of 262) of adult
(≥18 years old) outpatients developed diarrhea within 14
days after the start of treatment [43]. Patients that remain in
the hospital are similarly aﬀected. According to a prospective
study of hospitalized patients in Sweden, 12% (294 out of
2462) of patients ≥12 years old developed diarrhea within
45 days after the start of treatment [44]. However, certain
patientpopulationsinthehospitalappeartobeatanelevated
risk as 60% (9 out of 15) of individuals (ages 37–79) enrolled
in a cohort study of intensive care units developed diarrhea
within the ﬁrst week after of antibiotic treatment [45].
These data illustrate that diarrhea is a common complication
of antibiotic use and suggest that critically ill patients are
exquisitely susceptible to AAD.4 Interdisciplinary Perspectives on Infectious Diseases
An etiologic agent is not necessary for AAD, as certain
drugs can cause gastrointestinal dysfunction directly [42]. A
distinction can, then, be made between pathogen-associated
and pathogen-independent AAD in that Koch’s postulates
are not met in the classical sense. For example, if the bacteria
responsible for breaking down fermentable starches in the
colonareeliminatedbytheeﬀectofanantibiotic,anosmotic
diarrhea may present. In this scenario, the community and
not a deﬁned pathogen is responsible for the disease etiology.
To our knowledge, however, replicating the disease in an
otherwise na¨ ıve individual by establishing the “pathogenic
community” has not been shown.
A number of opportunistic pathogens can cause dis-
ease during antibiotic therapy, including Salmonella spp.,
Clostridiumperfringens,Klebsiellaoxytoca,S.aureus,Candida
albicans,a n dC. diﬃcile. Of these, C. diﬃcile is the most
common cause of pathogen-associated AAD (15%–25%),
the most common cause of severe disease, and it causes
nearly all cases of nosocomial pseudomembranous colitis
[46]. C. diﬃcile is an anaerobic, spore forming bacterium
that is commonly found in soil, humans, and animals [47].
This toxigenic gram-positive bacillus is asymptomatically
carried by 1%–3% of the human population, but is more
prevalent among infants [23], hospitalized patients (55.4%
of the hospital population in the Swedish AAD cohort study
mentioned above [44]w e r ep o s i t i v ef o rC. diﬃcile toxin),
older (≥60 years) patients [47–49], and healthcare personnel
that care for patients being treated with antibiotics [50].
This pathogen can cause disease in nonhospitalized patients
[51], where the main risk factors are antibiotic therapy,
protonpumpinhibitors, andtheuseofhistamine-2-receptor
antagonists [52].
Pseudomembranous colitis in the distal colon and rec-
tum is fatal in 6%–30% of cases [47]. Disease onset occurs
several days to several weeks after initial antibiotic treatment
and certain drugs, such as clindamycin, cephalosporins,
ﬂuoroquinolones, and β-lactams, are associated with greater
risk of CDAD [46, 53]. Oral antibiotic therapies with van-
comycin, metronidazole, bacitracin, teicoplanin, and fucidin
have been shown to be an eﬀective initial treatments for
CDAD [54]. A signiﬁcant number (20%–35%) of patients
develop recurrent illness caused by the same or diﬀerent
C. diﬃcile strains and symptoms arise several days (usually
>4) to several weeks after the apparent success of the initial
antibiotic therapy [55–57].
CDAD has been a recognized health problem in the
United States and many industrialized countries for more
than 30 years [58], but the epidemiology of the disease
is changing. The prevalence and severity (case fatality
rate) of CDAD continue to increase in spite of numerous
discoveries concerning its epidemiology, pathogenicity, and
treatment [53, 59]. This increasing trend is associated with
the emergence and spread of an epidemic strain referred to
as NAP1/BI (North American pulsed-ﬁeld type 1, ribotype
027, restriction endonuclease analysis type BI, toxinotype
III) [47, 60]. As a result, the average inhospital cost of
CDAD patients is estimated to be 54% more than non-
CDAD patients in the United States, adding an overall $1.1
billion to national health care costs [61]. Length of hospital
stay also increases with CDAD patients and ranges from an
average of 3.6 days for the total inpatient population to 16
days for surgical inpatients [62].
6. THE MICROBIAL ECOLOGY APPROACH TO
AAD AND CDAD
There are few data that assess changes in the human gut
microbiota during the course of AAD. The only sequence-
based,microbialecologystudytodatefolloweda39-year-old
male throughout an amoxicillin-clavulanic acid treatment
(875 and 125mg, resp., 2 times daily for 10 days) for acute
sinusitis [63]. The patient developed non-CDAD within 24
hours of the ﬁrst dose and symptoms persisted until 4 days
after the ﬁnal dose. Stool samples were taken 12 hours after
the ﬁrst dose (day 0), 4 days into the 10-day regime (day 4),
andat2weeksfollowingtheﬁnaldose(day24).Atotalof84,
74, and 84 randomly cloned 16S rRNA genes were sequenced
from each sample, respectively.
At4daysintotheamoxicillin-clavulanicacidtherapy,the
gut microbiota of this individual was markedly shifted. Rep-
resentationoftheBacteroidesgroupwentfromexclusivelyB.
fragilisonday0toalmostallB.distasonisonday4.Therewas
also a dramatic outgrowth of Enterobacteriaciae (most likely
E. coli). Lastly, all members of the Clostridial rRNA cluster
XIVa and Biﬁdobacteria groups (32% of the all sequences on
day 0) were lost or below the detection limit.
Twoweeksafterthelastdoseofantibiotic,themicrobiota
appeared to be recovering to day 0 composition. The B.
fragilisand Clostridial rRNA cluster XIVa groups rebounded,
while B. distasonis and Enterobacteriacea groups were drasti-
cally decreased or undetected. Interestingly, members of the
Clostridial rRNA cluster IV group were relatively unaﬀected
bytheantibiotictreatmentandweresampledatroughlyeven
numbers on all 3 sampling days. In contrast, members of the
Biﬁdobacteria group were lost or below detection by day 4
and remained so at day 24. These data suggest that (i) the
composition of the gut bacterial community is dramatically
shifted during antibiotic therapy, (ii) that resiliency to this
drug’s eﬀects is group speciﬁc, and (iii) that it may require
an extended period of time for the microbiota to recover to
the prestressed composition, if at all. More data are needed
to adequately assess the rate and extent of recovery from this
and other antibiotics and to assess how variable these eﬀects
are in the human population.
The association between CDAD and perturbations of the
gutmicrobiotaiswellestablishedbutpoorlyunderstood.For
example, animal (hamster and mouse) and in vitro models
show antagonism between conventional microbiota and C.
diﬃcile population growth [64]. These ﬁndings help to
explain the success of bacteriotherapy for recurrent-CDAD,
where the disease was resolved by rectal instillation of donor
stool [65, 66]. However, the use of probiotics and synthetic
mixtures of bacteria has had limited success [67] and is not
currently eﬃcacious as alternative therapies. The hope is
that a better understanding of the complexity of this system
during CDAD infection will lead to deﬁned manipulations
of patient microbiota that will both prevent establishment of
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To this end, Chang et al. recently applied the same
approach discussed above (16S rRNA gene sequencing)
to 7 patients with initial (n = 3) and recurrent (n =
4) CDAD and 3 control individuals from an outpatient
clinic [68]. Species level identity based on 97% nucleotide
similarity was determined for 125–184 16S rRNA genes per
individual. To gain insight into the overall bacterial diversity
of each patient’s fecal microbiota, rarefaction curves were
generated from these sequence data. Rarefaction is a method
of generating idealized taxonomic “collectors curves” from
community data through data resampling [69]. The shape
of the rarefaction curves is then indicative of the overall
complexity of the microbiota in each community, allowing
comparisonofthediversityofeachpatient’sfecalmicrobiota.
At this level of community sampling, inferences were
restricted to the most abundant members. However, and
without exception, the microbiota from control and initial
CDAD patients was more complex than the microbiota
from recurrent CDAD patients. Furthermore, the authors
were able to combine these data with those from the
non-CDAD-AAD patient [63] to show a clear association
between microbiota complexity and disease outcome (i.e.,
Controls>AAD>initial CDAD recurrent CDAD). This
study not only provides a support for the barrier function
againstC.diﬃcileestablishmentanddisease,butalsobecause
the sequences represent actual organisms, these data can be
used to identify potentially useful antagonistic relationships
in the community.
The 16S rRNA clone library approach is useful to study
interesting symbiotic associations in bacterial communities.
This and other techniques may also be useful in predicting
clinical outcomes based on their association with speciﬁc
consortia of bacteria. To do so requires a novel concep-
tualization of the disease process in that one particular
organism is not necessarily deﬁned as the causative agent,
but rather the entire community is involved in causing the
outcome. There is little information available to generate
these types of risk models, but the clinical potential in
using microbial ecological inferences to guide therapies
(i.e., tapering antibiotic treatments, probiotics, etc.) and
prevention certainly warrants further investigation.
7. CONCLUSIONSAND FUTURE DIRECTION
Comparativestudiesthatusemicrobialecologytechniquesto
analyze temporally sampled patients and control individuals
are a promising approach to complex disease research.
Traditional culture-based methods continue to be the gold
standard for disease diagnostics, but this approach can
only detect organisms that are easy to isolate and have
simple metabolic requirements. Since the vast majority of
the human gut microbiota is currently noncultivable, a
nonculture-based approach may be more useful for the
diagnosisandpredictionofclinicaloutcomes[70].Analyzing
the metagenome is such an approach and can be used to
identify members of complex bacterial communities based
on nucleotide variability in conserved genes [70, 71]. New
technologies, such as pyrosequencing, have recently become
available and attain the high throughput and resolution
required to make detailed community comparisons based on
more than one locus. An added beneﬁt of these technologies
is that reagents and chemistries are constantly being re-
engineered so that eﬃciency is maximized at lower cost.
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